JP2002522021A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002522021A5 JP2002522021A5 JP2000561317A JP2000561317A JP2002522021A5 JP 2002522021 A5 JP2002522021 A5 JP 2002522021A5 JP 2000561317 A JP2000561317 A JP 2000561317A JP 2000561317 A JP2000561317 A JP 2000561317A JP 2002522021 A5 JP2002522021 A5 JP 2002522021A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- polynucleotide
- nucleotide sequence
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 description 99
- 229920000023 polynucleotide Polymers 0.000 description 36
- 239000002157 polynucleotide Substances 0.000 description 36
- 229920001850 Nucleic acid sequence Polymers 0.000 description 31
- 210000004027 cells Anatomy 0.000 description 22
- 125000000539 amino acid group Chemical group 0.000 description 17
- 102000004965 antibodies Human genes 0.000 description 12
- 108090001123 antibodies Proteins 0.000 description 12
- 150000007523 nucleic acids Chemical group 0.000 description 11
- 229920002676 Complementary DNA Polymers 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 9
- 230000003042 antagnostic Effects 0.000 description 9
- 239000005557 antagonist Substances 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000000556 agonist Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 102000024070 binding proteins Human genes 0.000 description 3
- 108091007650 binding proteins Proteins 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 210000000987 Immune System Anatomy 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-Methionine Natural products CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 230000000295 complement Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000001105 regulatory Effects 0.000 description 2
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- 210000001124 Body Fluids Anatomy 0.000 description 1
- 230000035693 Fab Effects 0.000 description 1
- 210000003958 Hematopoietic Stem Cells Anatomy 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 210000003643 Myeloid Progenitor Cells Anatomy 0.000 description 1
- 241000658540 Ora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010047461 Viral infection Diseases 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 230000000692 anti-sense Effects 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 108091006028 chimera Proteins 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 230000002538 fungal Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9364398P | 1998-07-21 | 1998-07-21 | |
| US60/093,643 | 1998-07-21 | ||
| PCT/US1999/016424 WO2000005371A1 (en) | 1998-07-21 | 1999-07-21 | Keratinocyte derived interferon |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002522021A JP2002522021A (ja) | 2002-07-23 |
| JP2002522021A5 true JP2002522021A5 (de) | 2006-09-07 |
Family
ID=22240013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000561317A Pending JP2002522021A (ja) | 1998-07-21 | 1999-07-21 | ケラチノサイト由来のインターフェロン |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1100902A4 (de) |
| JP (1) | JP2002522021A (de) |
| KR (1) | KR100688051B1 (de) |
| CN (1) | CN1319137A (de) |
| AU (1) | AU765890B2 (de) |
| CA (1) | CA2335655A1 (de) |
| NZ (1) | NZ509402A (de) |
| WO (1) | WO2000005371A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60037978T2 (de) | 1999-12-08 | 2008-05-21 | Amgen Inc., Thousand Oaks | Interferon ähnliche moleküle, und deren verwendungen |
| EP1255833A2 (de) * | 2000-02-15 | 2002-11-13 | Curagen Corporation | Polypeptide und dafür kodierende nukleinsäure |
| EP1605045A3 (de) * | 2000-02-15 | 2006-03-01 | Curagen Corporation | Polypeptide und dafür kodierende Nukleinsäure |
| KR100975013B1 (ko) * | 2008-02-29 | 2010-08-09 | 김성일 | 원터치로 개폐되는 키홀더 |
| KR200457865Y1 (ko) * | 2009-09-11 | 2012-01-05 | 한국알프스 주식회사 | 자동차용 키 |
| CN108752457B (zh) * | 2018-05-23 | 2019-06-21 | 华中农业大学 | 一种来源于草鱼干扰素的衍生多肽及其应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0626448A3 (de) * | 1993-05-26 | 1998-01-14 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Verfahren zur Herstellung und Reinigung von alpha-Interferon |
-
1999
- 1999-07-21 EP EP99935752A patent/EP1100902A4/de not_active Withdrawn
- 1999-07-21 CA CA002335655A patent/CA2335655A1/en not_active Abandoned
- 1999-07-21 CN CN99811157A patent/CN1319137A/zh active Pending
- 1999-07-21 WO PCT/US1999/016424 patent/WO2000005371A1/en active IP Right Grant
- 1999-07-21 JP JP2000561317A patent/JP2002522021A/ja active Pending
- 1999-07-21 AU AU51161/99A patent/AU765890B2/en not_active Ceased
- 1999-07-21 KR KR1020017000891A patent/KR100688051B1/ko not_active IP Right Cessation
- 1999-07-21 NZ NZ509402A patent/NZ509402A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2865300B2 (ja) | ヒトｂ細胞刺激因子２レセプター蛋白質 | |
| EP0406272B2 (de) | Herstellung eines insulinähnlichen, wachstümsfaktor bindenden proteins | |
| JP2002516103A5 (de) | ||
| FI93025C (fi) | Rekombinantti lymfotoksiini | |
| JP2001513982A5 (de) | ||
| JP2002502589A5 (de) | ||
| JPH07222597A (ja) | 組換免疫グロブリンの調製方法 | |
| JP2002521055A5 (de) | ||
| EP2872163B1 (de) | Neue il-17a-verbindungsmoleküle und medizinische verwendungen davon | |
| JP2002518010A5 (de) | ||
| CA2225189A1 (en) | Canine factor viii gene, protein and methods of use | |
| JP2004516013A5 (de) | ||
| JP2005522986A5 (de) | ||
| WO1989012069A1 (en) | Recombinant techniques for production of novel natriuretic and vasodilator peptides | |
| JP2002522041A5 (de) | ||
| WO2003016489A2 (en) | Porcine leptin protein, antisense and antibody | |
| JP2004500037A5 (de) | ||
| JP2005518212A5 (de) | ||
| US20050158740A1 (en) | Variants of human glycoprotein hormone alpha chain: compositions and uses thereof | |
| JP2002522021A5 (de) | ||
| WO1998008866B1 (en) | Bau, a bin1 interacting protein, and uses therefor | |
| KR100382628B1 (ko) | 인터페론α/β결합단백질과이의제조및용도 | |
| JP2001522605A5 (de) | ||
| WO1997016550A1 (en) | Polypeptide fragments derived from the obese gene product | |
| AU740739B2 (en) | Bovine leptin protein, nucleic acid sequences coding therefor and uses thereof |